[1] WU S E，CHEN Y H，CHUNG C H，et al.Atopic dermatitis as a risk factor for herpes zoster infection independent of treatment：a nationwide population-based cohort study[J].Dermatitis，2023，34（3）：241-249.
[2] BIEBER T，SIMPSON E L，SILVERBERG J I，et al.Abrocitinib versus placebo or dupilumab for atopic dermatitis[J].N Engl J Med，2021，384（12）：1101-1112.
[3] GOODERHAM M J，FORMAN S B，BISSON-NETTE R，et al.Efficacy and safety of oral ja nus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis：a phase 2 randomized clinical trial[J].JAMA Dermatol，2019，155（12）：1371-1379.
[4] EICHENFIELD L F，FLOHR C，SIDBURY R，et al.Efficacy and safety of abrocitinib in com bination with topical therapy in adolescents with moderate-to-severe atopic dermatitis：the JADE TEEN randomized clinical trial[J].JA MA Dermatol，2021，157（10）：1165-1173.
